TGA Approves Axonics Sacral Neuromodulation System
Image credit: Axonics
US medtech, Axonics has been given a tick from the Therapeutic Goods Administration (TGA) to commence marketing its sacral neuromodulation system in Australia, in the treatment of adults with overactive bladder.
The Axonics F15 sacral neuromodulation system is comprised of a small, recharge-free implantable neurostimulator, which supplies constant current stimulation.
It can adjust the magnitude of stimulation in line with required symptom relief with minimal reprogramming.
“We are delighted to receive regulatory approval for our latest SNM system in Australia,” said Axonics CEO and Co-founder, Raymond Cohen in a statement.
“Our mission-driven team remains committed to innovating, supporting our dedicated physician customers and their patients, and raising awareness of our best-in-class incontinence therapies in the United States, Europe and Australia.”
Check out the press release via Axonics for further information.
